论文部分内容阅读
目的:观察对先兆流产患者行地屈孕酮与黄体酮胶丸治疗的临床疗效。方法:选取2015年2月至2016年5月我院保胎治疗后随访的68例先兆流产患者作为研究对象,将其按照入院时间分为参照组和观察组,每组34例,参照组患者行地屈孕酮治疗,观察组患者行黄体酮胶丸治疗,对两组患者的治疗效果进行比较。结果:治疗后,参照组患者的成功保胎率为91.2%,观察组患者的成功保胎率为88.2%,经统计学分析差异无意义,即P>0.05;参照组患者发生不良反应的概率为5.9%,观察组患者发生不良反应的概率为2.9%,经统计学分析差异无意义,即P>0.05;不同孕周两组患者的血清孕酮水平比较,经统计学分析差异无意义,即P>0.05。结论:先兆流产患者行地屈孕酮与黄体酮胶丸治疗均取得了良好的临床效果,且具有较高的安全性。
Objective: To observe the clinical efficacy of progesterone and progesterone capsules in patients with threatened abortion. Methods: From February 2015 to May 2016, 68 cases of threatened abortion patients who were followed up after tocolytic treatment in our hospital were selected as the research object. According to the time of admission, the patients were divided into the reference group and the observation group, 34 cases in each group, Row progesterone treatment, observation group patients underwent progesterone capsules treatment, the treatment effect of two groups of patients were compared. Results: After treatment, the success rate of miscarriage was 91.2% in the reference group and 88.2% in the observation group. There was no significant difference by statistical analysis (P> 0.05). The probability of adverse reactions in the reference group Was 5.9%. The probability of adverse reactions in the observation group was 2.9%. There was no significant difference by statistical analysis, ie, P> 0.05. Compared with the serum progesterone levels in two groups of gestational weeks, there was no significant difference by statistical analysis, Ie P> 0.05. CONCLUSIONS: Proximal abortion patients have achieved good clinical results in treating progesterone and progesterone capsules with high safety.